Rani Therapeutics Holdings Inc
For the period ended Dec 31, 2023. Filed Mar 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 20, 2024
RANI$0.57+5.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Net loss | $(67,883) | $(63,344) |
| Other comprehensive loss | ||
| Net unrealized gain (loss) on marketable securities | 121 | (149) |
| Comprehensive loss | $(67,762) | $(63,493) |
| Comprehensive loss attributable to non-controlling interest | (33,852) | (32,832) |
| Comprehensive loss attributable to Rani Therapeutics Holdings, Inc. | $(33,910) | $(30,661) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.